Your browser doesn't support javascript.
loading
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran, Salah-Eddin; Hofheinz, Ralf D; Pauligk, Claudia; Kopp, Hans-Georg; Haag, Georg Martin; Luley, Kim Barbara; Meiler, Johannes; Homann, Nils; Lorenzen, Sylvie; Schmalenberg, Harald; Probst, Stephan; Koenigsmann, Michael; Egger, Matthias; Prasnikar, Nicole; Caca, Karel; Trojan, Jörg; Martens, Uwe M; Block, Andreas; Fischbach, Wolfgang; Mahlberg, Rolf; Clemens, Michael; Illerhaus, Gerald; Zirlik, Katja; Behringer, Dirk M; Schmiegel, Wolff; Pohl, Michael; Heike, Michael; Ronellenfitsch, Ulrich; Schuler, Martin; Bechstein, Wolf O; Königsrainer, Alfred; Gaiser, Timo; Schirmacher, Peter; Hozaeel, Wael; Reichart, Alexander; Goetze, Thorsten O; Sievert, Mark; Jäger, Elke; Mönig, Stefan; Tannapfel, Andrea.
Afiliação
  • Al-Batran SE; Institute of Clinical Cancer Research, UCT University Cancer Center, Krankenhaus Nordwest, Frankfurt, Germany. Electronic address: albatran.salah@khnw.de.
  • Hofheinz RD; Medical Department III, Universitätsmedizin Mannheim, Mannheim, Germany.
  • Pauligk C; Institute of Clinical Cancer Research, UCT University Cancer Center, Krankenhaus Nordwest, Frankfurt, Germany.
  • Kopp HG; Medical Department II, University Hospital, Tübingen, Germany.
  • Haag GM; National Center for Tumor Diseases, University Hospital Heidelberg, Medical Oncology, Heidelberg, Germany.
  • Luley KB; Universitätsklinikum Schleswig-Holstein, Medical Department I Hematology/Oncology, Lübeck, Germany.
  • Meiler J; West German Cancer Center, Department of Medical Oncology, and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany.
  • Homann N; Klinikum Wolfsburg, Medical Department II, Wolfsburg, Germany.
  • Lorenzen S; Klinikum rechts der Isar der TU München, Medical Department III, Munich, Germany.
  • Schmalenberg H; Department of Internal Medicine II, University Hospital Jena, Germany.
  • Probst S; Klinikum Bielefeld, Department for Hematology and Oncology, Bielefeld, Germany.
  • Koenigsmann M; MediProjekt, Gesellschaft für Medizinstatistik und Projektentwicklung, Hannover, Germany.
  • Egger M; Ortenau Klinikum Lahr, Medical Department, Lahr, Germany.
  • Prasnikar N; Klinikum Ludwigsburg, Medical Department I, Ludwigsburg, Germany.
  • Caca K; Klinikum Ludwigsburg, Medical Department I, Ludwigsburg, Germany.
  • Trojan J; Medical Department I, Goethe University Medical Center, Frankfurt, Germany.
  • Martens UM; SLK-Kliniken, Medical Department III, Cancer Center Heilbronn-Franken, Heilbronn, Germany.
  • Block A; University Hospital Hamburg-Eppendorf, Department for Oncology and Hematology, Hamburg, Germany.
  • Fischbach W; Klinikum Aschaffenburg, Medical Department II, Aschaffenburg, Germany.
  • Mahlberg R; Klinikum Mutterhaus der Borromäerinnen, Medical Department I, Trier, Germany.
  • Clemens M; Klinikum Mutterhaus der Borromäerinnen, Medical Department I, Trier, Germany.
  • Illerhaus G; Universitätsklinikum Freiburg, Medical Department I, Freiburg, Germany.
  • Zirlik K; Universitätsklinikum Freiburg, Medical Department I, Freiburg, Germany.
  • Behringer DM; Augusta-Krankenanstalt, Department for Hematology, Oncology and Palliative Medicine, Bochum, Germany.
  • Schmiegel W; Department of Internal Medicine, Ruhr-University Bochum, Bochum, Germany.
  • Pohl M; Department of Internal Medicine, Ruhr-University Bochum, Bochum, Germany.
  • Heike M; Klinikum Dortmund, Medical Department, Dortmund, Germany.
  • Ronellenfitsch U; Department of Surgery, Universitätsmedizin Mannheim, Mannheim, Germany.
  • Schuler M; West German Cancer Center, Department of Medical Oncology, and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany.
  • Bechstein WO; Department of General and Visceral Surgery, Goethe University Medical Center, Frankfurt, Germany.
  • Königsrainer A; Department of Surgery and Transplantation, University Hospital, Tübingen, Germany.
  • Gaiser T; Department of Pathology, Universitätsmedizin Mannheim, Mannheim, Germany.
  • Schirmacher P; Institute of Pathology, University Hospital Heidelberg, Medical Oncology, Heidelberg, Germany.
  • Hozaeel W; Institute of Clinical Cancer Research, UCT University Cancer Center, Krankenhaus Nordwest, Frankfurt, Germany.
  • Reichart A; Institute of Clinical Cancer Research, UCT University Cancer Center, Krankenhaus Nordwest, Frankfurt, Germany.
  • Goetze TO; Institute of Clinical Cancer Research, UCT University Cancer Center, Krankenhaus Nordwest, Frankfurt, Germany.
  • Sievert M; Sanofi Genzymy, Berlin, Germany.
  • Jäger E; Department of Hematology-Oncology, Krankenhaus Nordwest, Frankfurt, Germany.
  • Mönig S; Hôpitaux Universitaires de Genève, Service de Chirurgie Viscérale, Geneva, Switzerland.
  • Tannapfel A; Institute for Pathology, Ruhr-University Bochum, Bochum, Germany.
Lancet Oncol ; 17(12): 1697-1708, 2016 Dec.
Article em En | MEDLINE | ID: mdl-27776843

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Junção Esofagogástrica Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Junção Esofagogástrica Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article